Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2006 Jun;21(6):630-5.
doi: 10.1111/j.1525-1497.2006.00459.x.

Osteoporosis risk assessment and ethnicity: validation and comparison of 2 clinical risk stratification instruments

Affiliations
Comparative Study

Osteoporosis risk assessment and ethnicity: validation and comparison of 2 clinical risk stratification instruments

Alvah R Cass et al. J Gen Intern Med. 2006 Jun.

Abstract

Background: Dual energy x-ray absorptiometry (DXA), coupled with early treatment, may reduce morbidity and mortality associated with osteoporosis. Clinical tools to enhance selection of women for DXA screening have not been developed or validated in an ethnically diverse population.

Objective: To compare the performance of the osteoporosis risk assessment instrument (ORAI) and the simple calculated osteoporosis risk estimation (SCORE) instrument across 3 racial/ethnic groups to identify women who would benefit from DXA scans.

Design: Blinded comparison of the instruments in a cross-sectional sample.

Participants: Two-hundred twenty-six postmenopausal women were recruited from a university-based family medicine clinic. Women with a prior diagnosis of osteoporosis or those taking bone active medications were excluded.

Measurements: Participants completed a questionnaire that contained the ORAI and the SCORE questions; 203 completed a DXA scan.

Results: The sensitivity and specificity for the ORAI (0.68, [0.49 to 0.88, 95% CI]; 0.66, [0.59 to 0.73, 95% CI]) and the SCORE instrument (0.54, [0.34 to 0.75, 95% CI]; 0.72, [0.65 to 0.78, 95% CI]) differed significantly from previous reports. Overall, the accuracy of the ORAI (66.5%) and SCORE instrument (70.0%) were similar (McNemar's test P value = .37). The accuracy between instruments differed significantly in African-American women (McNemar's test, P value <.001). In African Americans, the SCORE instrument correctly identified more women without osteoporosis, but missed 70% of those with osteoporosis.

Conclusions: The performance of the ORAI and SCORE instrument differed significantly from previous reports. Although both can reduce the use of DXA scans for screening for osteoporosis, lower sensitivities resulted in underrecognition of osteoporosis and may limit their clinical usefulness in an ethnically diverse population.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Enrollment schema. This figure illustrates the final disposition of all women approached for this study. Osteoporosis-related reasons included prior diagnosis of osteoporosis or current use of bone active medications other than estrogens. Miscellaneous reasons for exclusion included history of hip fracture, weight exceeded limit of DXA scanner, or other bone diseases. DXA, dual-energy x-ray absorptiometry; NHW, non-Hispanic white; AA, African American; HIS, Hispanic.

Similar articles

Cited by

References

    1. Ray N, Chan J, Thamer M, Melton M. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12:24–35. - PubMed
    1. Black D, Cummings S, Karpf D, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;347:1535–41. - PubMed
    1. Black D, Thompson D, Bauer D, et al. Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. J Clin Endocrinol Metab. 2000;85:4118–24. - PubMed
    1. Bone H, Greenspan S, McKeever C, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab. 2000;85:720–6. - PubMed
    1. Downs RJ, Bell N, Ettinger M, et al. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab. 2000;85:1783–8. - PubMed

Publication types